Accord BioPharma Announces Commercial Availability of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)

OSVYRTI®JUBEREQ®Positive

AI Analysis

Summary

Accord BioPharma announced commercial availability of denosumab biosimilars OSVYRTI® and JUBEREQ® to improve access to bone health treatments. The biosimilars are now available in the U.S. market.

Outcome Details

Commercial availability announced

Importance:4/10

Sentiment:

0.50

biosimilarsdenosumabcommercial launchbone healthspecialty pharma

Related Companies

$DFPH $HIT

Read the original article

Published by PR Newswire Pharma on July 23, 2026 12:05 PM

Read Original